Patents Assigned to Jazz Pharmaceuticals Ireland Limited
  • Publication number: 20190169589
    Abstract: The disclosure provides a modified protein that is a combination of (i) an L-asparaginase and (ii) one or more (poly)peptide(s), wherein the (poly)peptide consists solely of proline and alanine amino acid residues, and methods of preparation and use thereof.
    Type: Application
    Filed: December 19, 2018
    Publication date: June 6, 2019
    Applicants: XL-Protein GmbH, Jazz Pharmaceutical Ireland Limited
    Inventors: Lars Friedrich, Anne O'Donnell
  • Patent number: 10213400
    Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: February 26, 2019
    Assignee: JAZZ PHARMACEUTICALS IRELAND LIMITED
    Inventor: Mark Eller
  • Patent number: 10174302
    Abstract: The disclosure provides a modified protein that is a combination of (i) an L-asparaginase and (ii) one or more (poly)peptide(s), wherein the (poly)peptide consists solely of proline and alanine amino acid residues, and methods of preparation and use thereof.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: January 8, 2019
    Assignees: XL-protein GmbH, Jazz Pharmaceuticals Ireland Limited
    Inventors: Lars Friedrich, Anne O'Donnell
  • Publication number: 20180371446
    Abstract: The disclosure provides a modified protein that is a combination of (i) an L-asparaginase and (ii) one or more (poly)peptide(s), wherein the (poly)peptide consists solely of proline and alanine amino acid residues, and methods of preparation and use thereof.
    Type: Application
    Filed: August 7, 2017
    Publication date: December 27, 2018
    Applicants: XL-protein GmbH, Jazz Pharmaceuticals Ireland Limited
    Inventors: Lars Friedrich, Anne O'Donnell
  • Patent number: 9555017
    Abstract: Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: January 31, 2017
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventors: Clark P. Allphin, Michael DesJardin
  • Patent number: 9486426
    Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: November 8, 2016
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventor: Mark Eller
  • Patent number: 9132107
    Abstract: Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: September 15, 2015
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventors: Clark P. Allphin, Michael DesJardin
  • Patent number: 9050302
    Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: June 9, 2015
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventor: Mark Eller
  • Patent number: 8952029
    Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: February 10, 2015
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventor: Mark Eller